Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 130.50B | 125.08B | 119.18B | 117.75B | 99.92B | 119.03B |
Gross Profit | 43.56B | 42.69B | 38.96B | 38.42B | 34.59B | 40.21B |
EBITDA | 21.61B | 27.19B | 18.60B | 19.28B | 16.30B | 19.12B |
Net Income | 13.48B | 13.19B | 9.97B | 9.05B | 10.00B | 9.45B |
Balance Sheet | ||||||
Total Assets | 264.48B | 269.82B | 236.53B | 228.98B | 220.21B | 216.77B |
Cash, Cash Equivalents and Short-Term Investments | 79.19B | 90.62B | 76.89B | 75.82B | 67.16B | 62.67B |
Total Debt | 450.00M | 700.00M | 974.00M | 1.31B | 1.19B | 1.49B |
Total Liabilities | 44.28B | 49.94B | 40.14B | 41.31B | 43.54B | 45.83B |
Stockholders Equity | 192.20B | 187.15B | 166.27B | 160.29B | 151.50B | 143.23B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 15.35B | 7.00B | 10.05B | 11.30B | 8.34B |
Operating Cash Flow | 0.00 | 22.78B | 16.61B | 14.28B | 16.21B | 17.51B |
Investing Cash Flow | 0.00 | -5.78B | -12.30B | -6.66B | -7.26B | -8.73B |
Financing Cash Flow | 0.00 | -6.78B | -9.16B | -4.11B | -8.11B | -6.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | ¥146.57B | 10.69 | 13.95% | 2.98% | 4.47% | 29.40% | |
80 Outperform | ¥153.73B | 11.63 | 3.82% | 5.75% | -1.75% | ||
80 Outperform | ¥43.86B | 9.02 | 3.76% | 2.11% | 25.18% | ||
78 Outperform | ¥33.40B | 3.56 | 4.16% | 0.79% | 104.86% | ||
74 Outperform | ¥84.46B | 9.66 | 4.02% | 4.87% | 5.07% | ||
70 Outperform | ¥175.99B | 11.22 | 6.29% | 3.46% | 3.94% | 5.74% |
Nihon Parkerizing Co., Ltd. announced the repurchase of 645,000 shares of its common stock for approximately 801.8 million JPY, as part of a broader strategy approved in August 2024 to buy back up to 12 million shares. This move is intended to optimize the company’s capital structure and potentially increase shareholder value, reflecting a proactive approach in managing its equity and market presence.
Nihon Parkerizing Co., Ltd. announced corrections to its consolidated financial results for the fiscal year ended March 31, 2024, due to errors found in the consolidated statements of cash flows. The corrections slightly adjusted the cash flows from operating activities, but the overall financial position, including cash and cash equivalents at year-end, remained unchanged.
Nihon Parkerizing Co., Ltd. announced the repurchase of 661,500 shares of its common stock, totaling 801,052,200 JPY, as part of a broader buyback initiative authorized by its Board in August 2024. This move, executed through market purchases on the Tokyo Stock Exchange, reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
Nihon Parkerizing Co., Ltd. announced that its subsidiary, Parker Processing Co., Ltd., will propose a dividend payment of 3,042 million yen, subject to shareholder approval. This dividend will be recorded as non-operating income in Nihon Parkerizing’s non-consolidated financial statements for the fiscal year ending March 31, 2026, without affecting the consolidated business results.
Nihon Parkerizing Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 5.8% increase in net sales to 132,281 million yen. However, the company experienced a slight decline in operating and ordinary income, with a notable drop in comprehensive income by 39.5% compared to the previous year. The company forecasts a slight decrease in net sales and income for the next fiscal year, indicating potential challenges in maintaining growth momentum.
Nihon Parkerizing Co., Ltd. announced the repurchase of 916,600 shares of its common stock for a total of 1,028,123,700 JPY from April 1 to April 30, 2025, as part of a broader repurchase plan initiated in August 2024. This move is part of a strategic effort to manage its capital structure, potentially enhancing shareholder value and demonstrating confidence in the company’s financial health.